AR and endometrial cancer: In these diseases, NRs have proven to be effective therapeutic targets with numerous drugs targeting many NRs including estrogen receptor (ER) in breast, ovarian, and endometrial cancers, androgen receptor (AR) in prostate tumors, and glucocorticoid receptor (GR) in some hematological malignancies (14).